Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.66 |
| ▸ | BTK | Q06187 | 9/20 | 0.66 |
| ▸ | ATR | Q13535 | 8/20 | 0.61 |
| ▸ | IGF1R | P08069 | 4/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655575 | 0.93 | PIK3CD (0.66) | PIK3CDBTKATREGFR | |
| SCHEMBL16655710 | 0.83 | ATR (0.78) | PIK3CDBTKATREGFR | |
| SCHEMBL16655264 | 0.81 | PIK3CD (0.69) | PIK3CDBTKATREGFR | |
| SCHEMBL16655628 | 0.81 | PIK3CD (0.81) | PIK3CDBTKATR | |
| SCHEMBL16655349 | 0.80 | ATR (0.89) | PIK3CDBTKATREGFR | |
| SCHEMBL16655510 | 0.80 | ATR (0.68) | PIK3CDBTKATREGFR | |
| SCHEMBL13201507 | 0.80 | PIK3CD (0.65) | PIK3CDEGFR | |
| SCHEMBL16655764 | 0.80 | PIK3CD (1.00) | PIK3CDBTKATREGFR | |
| Hydrochloric Acid SCHEMBL23908619 | 0.79 | PIK3CD (0.98) | PIK3CDBTKATREGFR | |
| SCHEMBL16655861 | 0.78 | PIK3CD (0.83) | PIK3CDBTKATREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885BTK 1/4885ATR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.